A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: A high-dose study Academic Article uri icon

Overview

MeSH Major

  • Amides
  • Anti-Obesity Agents
  • Body Weight
  • Metabolic Syndrome X
  • Obesity
  • Pyridines

abstract

  • Taranabant at the 2- and 4-mg dose was effective in achieving clinically significant weight loss over 2 years and was associated with dose-related increases in adverse experiences. On the basis of these and other data, an assessment was made that the overall safety and efficacy profile of taranabant did not support its further development for the treatment of obesity.

publication date

  • May 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1038/ijo.2010.21

PubMed ID

  • 20157323

Additional Document Info

start page

  • 919

end page

  • 35

volume

  • 34

number

  • 5